COVID-19Regulatory

Abbott Labs Eclipses 1.4 Million Rapid Coronavirus Tests Shipped Across U.S.

May 5, 2020 / Bruce Japsen, Senior Contributor

Abbott Laboratories has shipped 1.4 million of its highly touted “rapid” molecular tests for the Coronavirus strain COVID-19 in the last month across the U.S., keeping ahead of its commitments to ramp up production.

The ability of Abbott to increase production and distribution of its ID NOW COVID-19 test is significant because it has been hailed in the ability of states across the U.S. to ramp up testing and re-open their economies. Abbott’s ID NOW COVID-19 test can deliver “positive results in as little as five minutes and negative results in 13 minutes.”

“We have shipped nearly 1.4 million of our rapid ID NOW tests to all 50 states, Washington D.C., Puerto Rico and the Pacific Islands,” Abbott said in an update posted on the company’s website Monday night. “The majority of these tests have been sent to outbreak hotspots and we’ve asked that customers prioritize frontline health care workers and first responders. We’re currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that.”

READ THE REST HERE

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button